Today: 11 June 2026
Citigroup stock holds near 52-week high as Barclays lifts target to $146 ahead of earnings
6 January 2026
1 min read

Citigroup stock holds near 52-week high as Barclays lifts target to $146 ahead of earnings

New York, January 6, 2026, 11:48 EST — Regular session

Citigroup (C.N) shares were up 0.1% at $123.42 in late-morning trade on Tuesday, after moving between $122.25 and $124.09 earlier in the session. Barclays analyst Jason Goldberg raised his price target on Citi — a forecast for the share price — to $146 from $115 and kept an Overweight rating, writing that “the trends that drove double-digit earnings growth” should carry into 2026. TipRanks

The stock’s pause comes as Wall Street extends a new-year rally and investors pivot to this week’s U.S. data and the start of quarterly reports for large banks. Shifts in rate expectations can quickly change how investors value lenders.

Friday’s U.S. Employment Situation report is due at 8:30 a.m. ET, according to the Labor Department. Traders have leaned more dovish after Minneapolis Fed President Neel Kashkari pointed to easing inflation and a possible rise in unemployment as reasons to cut rates, with markets pricing at least two cuts this year.

Citi jumped 3.88% on Monday to close at $123.30, marking a second straight gain and a new 52-week high. JPMorgan rose 2.63%, Bank of America gained 1.68% and Wells Fargo added 1.24%, while Citi’s volume hit 17.8 million shares, above its 50-day average of 12.4 million.

In a separate regulatory filing on Tuesday, Citigroup Global Markets Holdings filed a prospectus supplement for a structured note offering backed by Citigroup, SEC records show.

Analysts expect Citi to earn about $1.77 per share on revenue of roughly $21.0 billion in the fourth quarter, according to MarketBeat estimates. Investors will also watch the bank’s capital position and any change to its targets for 2026.

Focus is likely to fall on trading and investment-banking fees as well as expenses, after the lender’s reorganization. Net interest income, the spread between what a bank earns on loans and pays on deposits, can swing with rate moves.

But one-offs could muddy the picture: in late December, Citi said the planned sale of its remaining Russia operations would result in a pre-tax loss on sale for the fourth quarter, largely tied to currency translation adjustments — an accounting effect from converting foreign assets into dollars. Citi said the loss would be capital neutral to its common equity tier 1 ratio, a key measure of capital strength.

Bank earnings season begins next week, with JPMorgan Chase slated to report on Jan. 13 before other large lenders follow. Traders often use the early read on loan growth, credit costs and trading revenue to reset expectations for the group.

Citi said it will release its fourth-quarter results at about 8 a.m. ET on Wednesday, Jan. 14, and hold a webcast and conference call at 11 a.m. ET. The update is the next catalyst for Citi shares, with investors looking for guidance on expenses and the rate backdrop.

Stock Market Today

  • Corn Prices Dip Ahead of USDA WASDE Report with Mixed Export Data
    June 11, 2026, 10:50 AM EDT. Corn futures fell by 2 to 3 ¼ cents Thursday ahead of the U.S. Department of Agriculture's (USDA) latest WASDE report, which is expected to show a 6 million bushel cut to old crop carryout and a 10 million bushel reduction in new crop stocks. July corn futures settled at $4.19 per bushel, down ½ cent. Export sales data indicated old crop sales between 0.7 and 1.6 million metric tons, while new crop sales ranged from 200,000 to 500,000 metric tons. Brazilian and Argentine corn production estimates increased slightly to 135.8 million and 60.8 million metric tons respectively. Ethanol production and stocks showed minor changes, with ethanol exports rising to 155,000 barrels per day. Traders remain cautious ahead of USDA's official projections on global corn supply.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Uber stock hit by Melius “Sell” call as robotaxi threat sharpens; Wolfe sets $110 target
Previous Story

Uber stock hit by Melius “Sell” call as robotaxi threat sharpens; Wolfe sets $110 target

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure
Next Story

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure

Go toTop